Science Corporation’s vision-restoring chip wins EU approval
"The thing that the space needs is a company making $100 million a year of revenue," Science Corp. CEO Max Hodak said.
The EU approval of Science Corporation's vision-restoring chip is a significant milestone, marking a major breakthrough in the field of neurotechnology and regenerative medicine. This achievement not only validates the company's innovative approach but also paves the way for the commercialization of this life-changing technology. With the potential to restore vision to individuals with certain types of blindness, this chip has far-reaching implications for the estimated 285 million people worldwide living with visual impairments.
The approval also underscores the growing importance of the neural implant market, which is expected to experience rapid growth in the coming years. As the industry continues to advance, we can expect to see more companies like Science Corporation pushing the boundaries of what is possible with AI-powered medical devices. With CEO Max Hodak's ambitious goal of reaching $100 million in annual revenue, Science Corporation is poised to become a major player in this space, driving innovation and growth.
As the neural implant market continues to evolve, it's essential to watch for advancements in related areas, such as brain-computer interfaces and prosthetic limbs. The intersection of AI, neuroscience, and medicine will likely yield numerous breakthroughs, transforming the lives of millions of people worldwide. Keep an eye on Science Corporation's progress, as well as that of other companies and research institutions, to stay informed about the latest developments in this exciting and rapidly expanding field.
Originally reported by techcrunch.com. IPNews adds analysis for ai & agent economy readers.